In addition, refining and enriching patient populations for some degree of biological homogeneity is important, not only for the purpose of accurately defining activity of a specific investigational agent in this specific disease, but also for potentially identifying a group of patients with relapsed disease who may be candidates for more conventional or standard salvage therapy approaches. This will also aid in defining eligibility criteria and estimating accrual requirements for investigational approaches.
Vitals
GREGORY H. REAMAN, M.D., is chair of the United States–based Children's Oncology Group. He is also a professor of pediatrics at George Washington University School of Medicine and Health and member of the Division of Hematology-Oncology at the Children's National Medical Center, both in Washington.